WEKO3
アイテム
{"_buckets": {"deposit": "6700560c-6388-401d-91dc-4a297f0a8b23"}, "_deposit": {"id": "11484", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "11484"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00011484", "sets": ["456", "997"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Trastuzumab (Herceptin^[○!R]) Therapy in Breast Cancer(Molecular Targeted Therapy for Cancer)"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2007-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "625", "bibliographicPageStart": "622", "bibliographicVolumeNumber": "121", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. Trastuzumab (Herceptin^[○!R]), a recombinant monoclonal antibody against HER2 has been becoming a key drug for HER2-overexpressed breast cancer, moreover to be used in ajuvant and neoadjuvant settings.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "77988", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Koyama, Yu"}]}, {"nameIdentifiers": [{"nameIdentifier": "77989", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Hatakeyama, Katsuyoshi"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_relation_31": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://ci.nii.ac.jp/naid/110007146177", "subitem_relation_type_select": "URI"}}]}, "item_7_rights_15": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "本文データは学協会の許諾に基づきCiNiiから複製したものである"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "小山, 諭"}], "nameIdentifiers": [{"nameIdentifier": "77986", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "畠山, 勝義"}], "nameIdentifiers": [{"nameIdentifier": "77987", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "110007146177.pdf", "filesize": [{"value": "307.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 307300.0, "url": {"label": "110007146177.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/11484/files/110007146177.pdf"}, "version_id": "bbcc3453-bb2e-4282-a963-bdf80e9cb47e"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Trastuzumab (Herceptin^[○!R])", "subitem_subject_scheme": "Other"}, {"subitem_subject": "breast cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "adjuvant therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "neoadjuvant therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "HER2/neu", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "5 乳癌におけるトラスツヅマブ(ハーセプチン^[○!R])療法(シンポジウム がんの分子標的治療, 第628回新潟医学会)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "5 乳癌におけるトラスツヅマブ(ハーセプチン^[○!R])療法(シンポジウム がんの分子標的治療, 第628回新潟医学会)"}, {"subitem_title": "5 乳癌におけるトラスツヅマブ(ハーセプチン^[○!R])療法(シンポジウム がんの分子標的治療, 第628回新潟医学会)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "997"], "permalink_uri": "http://hdl.handle.net/10191/32855", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-08-07"}, "publish_date": "2015-08-07", "publish_status": "0", "recid": "11484", "relation": {}, "relation_version_is_last": true, "title": ["5 乳癌におけるトラスツヅマブ(ハーセプチン^[○!R])療法(シンポジウム がんの分子標的治療, 第628回新潟医学会)"], "weko_shared_id": null}
5 乳癌におけるトラスツヅマブ(ハーセプチン^[○!R])療法(シンポジウム がんの分子標的治療, 第628回新潟医学会)
http://hdl.handle.net/10191/32855
http://hdl.handle.net/10191/32855b24ca378-47c0-479a-b28e-11f73fb8f311
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-08-07 | |||||
タイトル | ||||||
タイトル | 5 乳癌におけるトラスツヅマブ(ハーセプチン^[○!R])療法(シンポジウム がんの分子標的治療, 第628回新潟医学会) | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | 5 乳癌におけるトラスツヅマブ(ハーセプチン^[○!R])療法(シンポジウム がんの分子標的治療, 第628回新潟医学会) | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Trastuzumab (Herceptin^[○!R]) | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | breast cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | adjuvant therapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | neoadjuvant therapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | HER2/neu | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | Trastuzumab (Herceptin^[○!R]) Therapy in Breast Cancer(Molecular Targeted Therapy for Cancer) | |||||
著者 |
小山, 諭
× 小山, 諭× 畠山, 勝義 |
|||||
著者別名 | ||||||
識別子 | 77988 | |||||
識別子Scheme | WEKO | |||||
姓名 | Koyama, Yu | |||||
著者別名 | ||||||
識別子 | 77989 | |||||
識別子Scheme | WEKO | |||||
姓名 | Hatakeyama, Katsuyoshi | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. Trastuzumab (Herceptin^[○!R]), a recombinant monoclonal antibody against HER2 has been becoming a key drug for HER2-overexpressed breast cancer, moreover to be used in ajuvant and neoadjuvant settings. | |||||
書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 121, 号 11, p. 622-625, 発行日 2007-11 |
|||||
出版者 | ||||||
出版者 | 新潟医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00290440 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00182415 | |||||
権利 | ||||||
権利情報 | 本文データは学協会の許諾に基づきCiNiiから複製したものである | |||||
著者版フラグ | ||||||
値 | publisher | |||||
異版である | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | URI | |||||
関連識別子 | http://ci.nii.ac.jp/naid/110007146177 |